Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MmrPSpVv[3Srb36gRZN{[Xl? NF32V3oxNjYEoN88US=> NFT4d3AzPCCq NF;FcGF4[XSnch?= M{niWY1w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ M4nWNVI2OTJ|MEiy
Eca109 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\XVFlQOC53L{KuOU82KM7:TR?= NHTZOG0zPC92OD:3NkBp NYLHSWpUf2G2ZYK= MljVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= NIjh[2UzPTF{M{C4Ni=>
Eca109 MUnGeY5kfGmxbjDBd5NigQ>? M{nCZlAvPcLizszN NYC3coMxPi9zMj:yOEBp MX73ZZRmeg>? NWLDcFl2cW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> NVjvWZFuOjVzMkOwPFI>
Eca109 Mo\USpVv[3Srb36gRZN{[Xl? NIm2eWsxNjYEoN88US=> M3HacVI1KGh? M4DrVZdifGW{ NXXIdHdWcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NHrMOo8zPTF{M{C4Ni=>
Eca109 M13YXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDqbGcxNjYEoN88US=> MUeyOEBp NEHNWmJ4[XSnch?= M2T1WYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> NXvyNVBzOjVzMkOwPFI>
Eca109 NWKyNm86TnWwY4Tpc44hSXO|YYm= NEjmdY8xNjVxMTFOwG0> NV6zeZN{OjRiaB?= MlHQe4F1\XJ? MUDk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz NGj1T|czPTF{M{C4Ni=>
SW1116  M3nhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjzNE42NzFxMj:1JO69VQ>? MXq0PEBp NH;wbGJFVVOR NW\5UYoy\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? NH;4eo0zPDh5NEK4Oi=>
LOVO M2HSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlUwOS9{L{Wg{txO Moe5OFghcA>? MnTXSG1UVw>? MoPp[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NFHSW2YzPDh5NEK4Oi=>
SW1116  NXnsepJjTnWwY4Tpc44hSXO|YYm= MVGxNEDPxE1? M2PldlQ5KGh? NWnTRYo5TE2VTx?= MmfZbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MojwNlQ5PzR{OE[=
LOVO MnHjSpVv[3Srb36gRZN{[Xl? NEPCWpUyOCEQvF2= NHLoZYM1QCCq MmTQSG1UVw>? NWLSc3BGcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MXmyOFg4PDJ6Nh?=
SW1116  M1LSWGFxd3C2b4Ppd{BCe3OjeR?= M{fZSlExKM7:TR?= NUDCXGZqPDhiaB?= NHTKcGNFVVOR M17zb4VvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MluzNlQ5PzR{OE[=
LOVO M1vxcmFxd3C2b4Ppd{BCe3OjeR?= M1zQOlExKM7:TR?= M4TPW|Q5KGh? MXjEUXNQ MX7lcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NVTxZ5hROjR6N{SyPFY>
RPMI-8226 MnvqRZBweHSxc3nzJGF{e2G7 NETVcWcyNzJizszN NHj5epU1QC95Mj:5OkBp MlPjSG1UVw>? M{PHU4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NELndWUzPDh|M{GwPC=>
OPM-2  NVX2O5hCSXCxcITvd4l{KEG|c3H5 MWOxM|Ih|ryP M135dlczNzl4L{GyNEBp MXnEUXNQ M3LKWolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXTUZYViOjR6M{OxNFg>
JJN3  MYrBdI9xfG:|aYOgRZN{[Xl? MVywMlUwOSEQvF2= NYnBOIZVOjRxNEigbC=> NFP2cnhFVVOR M3LJOIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWq4d|l4OjR6M{OxNFg>
NCI-H929  M{P2[GFxd3C2b4Ppd{BCe3OjeR?= MV:xM|Ih|ryP MlroO|IwQTZxMUKwJIg> MnLUSG1UVw>? NHn4[|ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmTwNlQ5OzNzMEi=
RPMI-8226 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTpNU8zKM7:TR?= NFWxeG8zPC92OD:3NkBp Mn7BSG1UVw>? NUO5SlRV[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NX64fIlzOjR6M{OxNFg>
OPM-2  M3e0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILwSooyNzJizszN M3;HfVI1NzR6L{eyJIg> MXPEUXNQ MVfh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NYDPVW5SOjR6M{OxNFg>
JJN3  M2jkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP0ZncxNjVxMTFOwG0> MmLYNlQwPDhxN{KgbC=> NWDucVRpTE2VTx?= Ml\jZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NEPoNoUzPDh|M{GwPC=>
NCI-H929  MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfiOZl5OS9{IN88US=> M3;TNlI1NzR6L{eyJIg> NGrCToFFVVOR M4T6WoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MoDxNlQ5OzNzMEi=
HeLa NHLPS45McW6jc3WgRZN{[Xl? MnTNT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> NVuweFRwOjR5OECwPVg>
HeLa MUTLbY5ie2ViQYPzZZk> NH74NlhMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> M{LtUlI1PzhyMEm4
HeLa MmrVT4lv[XOnIFHzd4F6 M2\yPWtqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> MXuyOFc5ODB7OB?=
HeLa M3XYSWtqdmG|ZTDBd5NigQ>? NEPPTVFMcT1zND60JOKyKDRwNjFOwG0h\m:{IHjDUnQ{ MlnvNlQ4QDByOUi=
NB4 M4rPZ2Z2dmO2aX;uJGF{e2G7 NX73TWdQOi53L{WvO{42NzFyIN88US=> MX[yOEBp NV;TXllKTE2VTx?= NYDrbmtNcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? M2PYR|I1PDh2OEew
CD4+ CD25− T  M1jl[mZ2dmO2aX;uJGF{e2G7 MljtNU82KM7:TR?= NXXGRnI{emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w M2jUWFI1PDd4M{[w
BV-173 NGH4S4ZCeG:ydH;zbZMhSXO|YYm= NVr1O|ZCOC5{NT:wMlUwOC55NT:xJO69VQ>? NVTXcm9OPDhxN{KvPVYhcA>? M3vDOeKhWEKV NWn4VplPcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MnHFNlQ1OjN4MUO=
ML-1 NYjSd|BNSXCxcITvd4l{KEG|c3H5 MljINE4zPS9yLkWvNE44PS9zIN88US=> MnL4OFgwPzJxOU[gbC=> M2m1O:KhWEKV NWHYWG5ncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M4DCW|I1PDJ|NkGz
HL-60 M{TIeGFxd3C2b4Ppd{BCe3OjeR?= M{DH[|AvOjVxMD61M|AvPzVxMTFOwG0> NXvVOXRTPDhxN{KvPVYhcA>? M{n1[eKhWEKV M2\ubolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NHXzW2EzPDR{M{[xNy=>
KG-1a MXvBdI9xfG:|aYOgRZN{[Xl? M3z1dFAvOjVxMD61M|AvPzVxMTFOwG0> M2HyNVQ5Nzd{L{m2JIg> M1\xWeKhWEKV M1jsVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MYSyOFQzOzZzMx?=
BV-173 MXrGeY5kfGmxbjDBd5NigQ>? MnzsNlUxNzVyMH7N M2juWlQ5KGh? Ml;KxsBRSlN? NW\I[JNlcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MWmyOFQzOzZzMx?=
CEM M17OSmZ2dmO2aX;uJGF{e2G7 NFjWUIozPTBxNUCwcm0> NESzXJk1QCCq M3HEc:KhWEKV MXXpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MnTBNlQ1OjN4MUO=
HL-60 NY\XS2dMTnWwY4Tpc44hSXO|YYm= NF7IfHkzPTBxNUCwcm0> MXG0PEBp M1jrVeKhWEKV M1voR4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MnPQNlQ1OjN4MUO=
ML-1 M3X0dGZ2dmO2aX;uJGF{e2G7 MVqyOVAwPTBybl2= NWLlcFdWPDhiaB?= NFPndI7DqFCEUx?= NIS1O|lqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M2TodlI1PDJ|NkGz
DLD-1 MkjtSpVv[3Srb36gRZN{[Xl? MkO5NlUxNzVyMH7N NIf4[Wg1QCCq M{\1WeKhWEKV NX\LdWJ6\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M1vDSFI1PDJ|NkGz
HCT-116 NI\KeHpHfW6ldHnvckBCe3OjeR?= NUO5OZZUOjVyL{WwNI5O MnPnOFghcA>? NUPPN2Y3yqCSQmO= NVSweZBu\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MlfrNlQ1OjN4MUO=
U937-A/E-9/14/18  NHPEdINCeG:ydH;zbZMhSXO|YYm= MWOwMlAyNzBwMT:xM|ExKM7:TR?= NEjWe2g1QCCq Mkn4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3XXV|I1OzByNEW2
HT29 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\4O|IhcA>? NX;Z[2xIUUN3ME2xOFAxyrFzN{mg{txO NYPERoZSOjRzN{KwOlE>
SW48 NE\wSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[0b2s4OiCq M1iwWWlEPTB;MUWuNuKyPi5{IN88US=> MlnONlQyPzJyNkG=
HCT116 NFvmUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[5e244OiCq MXrJR|UxRTFwN9MxNE41KM7:TR?= NV21O29qOjRzN{KwOlE>
HepG2 NI\xTYFHfW6ldHnvckBCe3OjeR?= NHX3S4wxNjVxMTFOwG0> MUOyOEBp MlvLSG1UVw>? M1P4fJVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NVn3TFd7OjRzNE[4O|Q>
LS174T M4KwfmZ2dmO2aX;uJGF{e2G7 NH\qNVYxNjVxMTFOwG0> MnPKNlQhcA>? MXLEUXNQ NHnUXoZt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> MWeyOFE1Pjh5NB?=
HepG2 NIrL[IxCeG:ydH;zbZMhSXO|YYm= NX\hfYl6OS9zMD:xNFAh|ryP MlHBO{Bl NWfLeYw1TE2VTx?= Ml;FbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXOxSG5iOjRzNE[4O|Q>
LS174T M3X0cGFxd3C2b4Ppd{BCe3OjeR?= MmHtNU8yOC9zMECg{txO MWW3JIQ> MnfoSG1UVw>? M1XiZolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXyyOFE1Pjh5NB?=
QBC-939 NXzEU49VSXCxcITvd4l{KEG|c3H5 M1n5flEwOTBxMUCwJO69VQ>? MmPoO{Bl M2rWU2ROW09? NV7QcoZ2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV;WVmlMOjRzNE[4O|Q>
U251 MUXBdI9xfG:|aYOgRZN{[Xl? M{jKfFEwOTBxMUCwJO69VQ>? MnPtO{Bl MX7EUXNQ NInSdHlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnnwNlQyPDZ6N{S=
HL-60 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe5dYcyKM7:TR?= NH\vTo81QCCq NFm2cnRqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MXKyOFAxODN{NB?=
MDA‑MB‑453 MUjGeY5kfGmxbjDBd5NigQ>? MmXaNE4zNzFizszN MX[3NkBp MX;jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M4jvUFI{QDR2MkK4
HCC1569 MofBSpVv[3Srb36gRZN{[Xl? MneyNE4zNzFizszN M1jzOlczKGh? NIXDVlFk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NVfDdY51OjN6NESyNlg>
BT‑474 NGDqT25HfW6ldHnvckBCe3OjeR?= NFXhR4MxNjJxMTFOwG0> Mlz6O|IhcA>? M16xToNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NU[xenR{OjN6NESyNlg>
AGS NWDK[5BbSXCxcITvd4l{KEG|c3H5 MV:1M|ExNzJyL{WwJO69VQ>? M4nBTVQ5yqCqwrC= NEPlW3ZFVVOR M1m1OIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NXjwXXNWOjN3OEK3PFQ>
A549 M4\UTGFxd3C2b4Ppd{BCe3OjeR?= NEe3OJU2NzFyL{KwM|UxKM7:TR?= NYPHOopEPDkEoHlCpC=> MlTrSG1UVw>? NFfncWpqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NUnybYR2OjN3OEK3PFQ>
AGS  NYDk[pJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV21M|ExNzJyL{WwJO69VQ>? Mlv3OFjDqGkEoB?= NHPoN3RFVVOR NFjOd2FqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> M4H2b|I{PTh{N{i0
Kasumi-1 NHvNfmtCeG:ydH;zbZMhSXO|YYm= MX[wMlUh|ryP MX20POKhcMLi Mnrp[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MlPtNlM1QTN|NEi=
OCI-AML3 NYnuRoNESXCxcITvd4l{KEG|c3H5 MWmyMlUh|ryP M3H2[FQ5yqCqwrC= MkfD[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MoS5NlM1QTN|NEi=
MV4-11 MXvBdI9xfG:|aYOgRZN{[Xl? MnGxNk42KM7:TR?= MljwOFjDqGkEoB?= M3\EOYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MYmyN|Q6OzN2OB?=
NK  MYfDfZRwfG:6aYT5JGF{e2G7 M{PNTlAvODJvMkCg{txO M3TDVVUh\A>? NEnOT5hl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n NIT3XI8zOzN{OEC4PC=>
NK  MmfDRZBweHSxc3nzJGF{e2G7 NWfTdmNsOC5yMj2yNEDPxE1? MofWOUBl NFHTZVFl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NFLuTGIzOzN{OEC4PC=>
NK  NFvyWVhHfW6ldHnvckBCe3OjeR?= NX[wS|EyOC5yMT2yNEDPxE1? NGTsb2U2KGR? NIruNVFk[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm MlraNlM{OjhyOEi=
MOLT4/DNR M373eGZ2dmO2aX;uJGF{e2G7 Ml3SOUDPxE1? M2rv[VQh\A>? NE\QS5pz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MX:yN|A3ODV5MB?=
Jurkat/DOX M3ywWWZ2dmO2aX;uJGF{e2G7 NIHE[YY2KM7:TR?= NWnmOXBwPCCm M2LMSZJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NIDrWZYzOzB4MEW3NC=>
MOLT4/DNR MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUm1JO69VQ>? MVu0JIQ> NGXXNplz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 NXvhXplMOjNyNkC1O|A>
Jurkat/DOX NVjqTWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHJUnA2KM7:TR?= NXfpdWc4PCCm MVjy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NHS3bnczOzB4MEW3NC=>
ccRCC  MX;BdI9xfG:|aYOgRZN{[Xl? NGPsWYUxNjBzLUGw{txO NWfJdFZ[PzJiaB?= NIDE[4hFVVOR M2fG[4hieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NHX6ZWgzOjh{NkS2Oy=>
TNBC  NYHqOJI3SXCxcITvd4l{KEG|c3H5 NHXJ[IUxNjBzLUGw{txO M{XRRlczKGh? NF;xcnFFVVOR NV3McJo5cGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MVeyNlgzPjR4Nx?=
A498 NFLGbJRCeG:ydH;zbZMhSXO|YYm= NEm1[YgxNjBzLUGw{txO NX3NToNIPzJiaB?= M2rWS2ROW09? NH3hZZRqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NE\XNowzOjh{NkS2Oy=>
KIJ265T MXHBdI9xfG:|aYOgRZN{[Xl? Mkf3NE4xOS1zMN88US=> NHvRNGk4OiCq MmPPSG1UVw>? M33Ofolv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NYrWU5NtOjJ6Mk[0Olc>
MDA-231 NU\2cYx5SXCxcITvd4l{KEG|c3H5 NUL1S2VqOC5yMT2xNO69VQ>? NVHGNW1uPzJiaB?= NXr0OVRHTE2VTx?= M{C4O4lv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MmPlNlI5OjZ2Nke=
BT-20 NXzibXg5SXCxcITvd4l{KEG|c3H5 MV6wMlAyNTFyzszN MoD0O|IhcA>? NWLufHRpTE2VTx?= MkDibY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NVyyZ3BmOjJ6Mk[0Olc>
U937 NI\JfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH2fXQ2NTJyIN88US=> NID2OWEzPC92OD:3NkBp Mk\2bY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MVWyNlc3PzB{MR?=
HL60 NFjhOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHhOU0zOCEQvF2= NVG2dXlLOjRxNEivO|IhcA>? MorNbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M2nBSlIzPzZ5MEKx
U937 NViyPI1MSXCxcITvd4l{KEG|c3H5 M1LqfVE2KM7:TR?= MViyOE81QC95MjDo M1GzUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NH7CSYwzOjd4N{CyNS=>
HL60 NFW3ZYpCeG:ydH;zbZMhSXO|YYm= NVfCOGEzOTVizszN M13GeVI1NzR6L{eyJIg> MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFHaU3UzOjd4N{CyNS=>
LS411N  NGD0SmpCeG:ydH;zbZMhSXO|YYm= NYHYTGNNOC53IN88US=> NV;k[IZxPzJiaB?= MWDpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? MkTVNlI1PjF4OUW=
MDA-MB-231 M13BWWFxd3C2b4Ppd{BCe3OjeR?= MYKxNEDPxE1? NXS4WXFGPDhiaB?= MnTTdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVi2U2pIOjF6OEe2PVc>
MCF-7  NV3wd4VOSXCxcITvd4l{KEG|c3H5 MXixNEDPxE1? MUi0PEBp MW\y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmPwNlE5QDd4OUe=
A375 NHfKPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOwMlUh|ryP MXWxM|UwQCCm NEfZdFhqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NEPFeVczOTd7Nk[yNi=>
SKMEL1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGwMlUh|ryP M4n1TFEwPS96IHS= M2HVPIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MmfUNlE4QTZ4MkK=
SKMEL3 NYLqNogyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknQNE42KM7:TR?= Mme2NU82NzhiZB?= M3jXR4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M4n3NFIyPzl4NkKy
SKMEL28 NFXnV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm3eVVqOC53IN88US=> NH;Gb2gyNzVxODDk NIPjZldqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MYiyNVc6PjZ{Mh?=
MeWo NUPzUJBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M171OFAvPSEQvF2= MXOxM|UwQCCm NXyz[m1VcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MlHFNlE4QTZ4MkK=
B16 M2\5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK1dpZ3OC53IN88US=> MWOxM|UwQCCm NF\zVJZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M3rnRlIyPzl4NkKy
Ly 1 M{XiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ifZlEOjRiaB?= NFTCU|dKSzVyPUeuN{DPxE1? MVmyNVc4OjB2OR?=
Ly 7 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nlOlI1KGh? NIWwTFJKSzVyPUGwMlch|ryP NFPHSlAzOTd5MkC0PS=>
Su-DHL6 NH3DT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:yOEBp M1HDPWlEPTExvK6yNEDPxE1? MYGyNVc4OjB2OR?=
Ly 10 NFXycWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq3NlQhcA>? MojqTWM2OO,:nkKwJO69VQ>? NETue4IzOTd5MkC0PS=>
RIVA NUj3eJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\YNlQhcA>? NYrDdHBRUUN3MP-8olIxKM7:TR?= MojKNlE4PzJyNEm=
Su-DHL2 NVX6RWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r3UlI1KGh? MlXmTWM2OO,:nkKwJO69VQ>? MofnNlE4PzJyNEm=
Ly 1 NEDCNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[4fVQ5KGh? Mkj1TWM2OD1yLkO0JO69VQ>? M3jadVIyPzd{MES5
Ly 7 M2\SSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITEd2I1QCCq NVLsd3l4UUN3ME2wMlAzPSEQvF2= Mlf0NlE4PzJyNEm=
Su-DHL6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi0PEBp NUSwXI11UUN3MP-8olIxKM7:TR?= MX2yNVc4OjB2OR?=
Ly 10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[0PEBp MXfJR|UxRTFwODFOwG0> NY\NVJA3OjF5N{KwOFk>
RIVA M4PCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvJU2M1QCCq M{\mcmlEPTExvK6yNEDPxE1? M1TYOFIyPzd{MES5
Su-DHL2 M{DZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jRdVQ5KGh? NGTofXNKSzVyPUG3MlQh|ryP NIPuW3UzOTd5MkC0PS=>
Ly 1 NEHldJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp MXXJR|UxRTBwMEGg{txO MXWyNVc4OjB2OR?=
Ly 7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVTlczKGh? MlHLTWM2OD1yLkCxPEDPxE1? MVGyNVc4OjB2OR?=
Su-DHL6 M{Gycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjGOHhwPzJiaB?= MkPYTWM2OD1zLk[g{txO M1f6VFIyPzd{MES5
Ly 10 NETQeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5THd{PzJiaB?= MULJR|UxRTFwMjFOwG0> M2rIS|IyPzd{MES5
RIVA MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkO|IhcA>? MUPJR|Ux97zgMkCg{txO M1nIPVIyPzd{MES5
Su-DHL2 M2HIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n3d|czKGh? MVfJR|UxRTFzLkKg{txO NXT6emh6OjF5N{KwOFk>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID